| 000 | 01607 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516045708.0 | ||
| 264 | 0 | _c20120202 | |
| 008 | 201202s 0 0 eng d | ||
| 022 | _a1502-4725 | ||
| 024 | 7 |
_a10.3109/08039488.2011.590603 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLindström, Eva | |
| 245 | 0 | 0 |
_aA pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. _h[electronic resource] |
| 260 |
_bNordic journal of psychiatry _cDec 2011 |
||
| 300 |
_a403-13 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntipsychotic Agents _xeconomics |
| 650 | 0 | 4 | _aAripiprazole |
| 650 | 0 | 4 |
_aBenzodiazepines _xeconomics |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aEconomics, Pharmaceutical |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHaloperidol _xeconomics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xeconomics |
| 650 | 0 | 4 |
_aIndoles _xeconomics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aModels, Economic |
| 650 | 0 | 4 | _aNational Health Programs |
| 650 | 0 | 4 | _aOlanzapine |
| 650 | 0 | 4 |
_aPiperazines _xeconomics |
| 650 | 0 | 4 |
_aQuinolones _xeconomics |
| 650 | 0 | 4 |
_aRisperidone _xeconomics |
| 650 | 0 | 4 |
_aSchizophrenia _xdrug therapy |
| 650 | 0 | 4 | _aSweden |
| 700 | 1 | _aEberhard, Jonas | |
| 700 | 1 | _aFors, Björn M | |
| 700 | 1 | _aHansen, Karina | |
| 700 | 1 | _aSapin, Christophe | |
| 773 | 0 |
_tNordic journal of psychiatry _gvol. 65 _gno. 6 _gp. 403-13 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/08039488.2011.590603 _zAvailable from publisher's website |
| 999 |
_c21018064 _d21018064 |
||